CalciMedica, a clinical-stage biotechnology company targeting CRAC channels for the treatment of inflammatory diseases, announced it had raised $15 million in a Series C financing round led by Valence Life Sciences.
The funds from this Series C financing will be used to advance ongoing clinical trials evaluating CRAC channel inhibitor, Auxora, in patients with COVID-19 pneumonia as well as to speed up commercial manufacturing for the drug.
Read more about CalciMedica here.
Image by Gerd Altmann from Pixabay
